KBY Biotech Indexv0.0.34
Search
← Pipeline|Peminaritide

Peminaritide

NDA/BLA
ITO-1159
By iTeos
Source: Trial-derived·Trials: 2
Modality
Cell Therapy
MOA
JAK1/2i
Target
CD20
Pathway
Lipid Met
CKDBCC
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
~May 2019
→ ~Aug 2020
Phase 3
~Nov 2020
→ ~Feb 2022
NDA/BLA
May 2022
→ Jan 2030
NDA/BLACurrent
NCT08812278
2,558 pts·CKD
2023-02→2030-01·Terminated
NCT03318186
2,347 pts·CKD
2022-05→2028-12·Terminated
4,905 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-12-272.7y awayPh3 Readout· CKD
2030-01-053.8y awayPh3 Readout· CKD
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
NDA/BLA
Termina…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-12-27 · 2.7y away
CKD
Ph3 Readout
2030-01-05 · 3.8y away
CKD
Terminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT08812278NDA/BLACKDTerminated2558Mayo
NCT03318186NDA/BLACKDTerminated2347NT-proBNP
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-8637Johnson & JohnsonNDA/BLACD20WEE1i
LisolucimabNovartisApprovedCD20KRASG12Ci
ABB-8985AbbViePhase 2CD20MALT1i
FixanesiranAbbViePreclinicalRETJAK1/2i
MotavorutinibAmgenPhase 3CDK4/6JAK1/2i
VRT-9481Vertex PharmaPhase 1/2MeninJAK1/2i
ARG-3265ArgenxPhase 1/2CD20CDK2i
SovarelsinBioMarinPhase 2CFTRJAK1/2i
PeminaritideSareptaNDA/BLAPLK4JAK1/2i
NiramavacamtenHansoh PharmaPhase 2SGLT2JAK1/2i